Exploring Biased Agonism at FPR1 as a Means to Encode Danger Sensing

Area of Science:

• Pharmacology
• Cellular Biology
• Immunology

Background:

• Biased signaling in G protein-coupled receptor (GPCR) research offers potential for targeted drug development.
• Human formyl peptide receptor 1 (FPR1) detects N-formylated peptides from bacteria and mitochondria, but also responds to non-formylated agonists.
• The hypothesis posits that biased agonism provides an additional layer of FPR1 signaling for threat source discrimination.

Purpose of the Study:

• To investigate biased agonism in FPR1 signaling.
• To determine if FPR1 can discriminate between bacterial and mitochondrial threat sources via biased signaling.
• To analyze FPR1 agonist-evoked responses across cAMP inhibition, receptor internalization, and ERK activation pathways.

Main Methods:

• Comparative analysis of FPR1 agonist-evoked responses across three signaling pathways (cAMP inhibition, internalization, ERK activation).
• Analysis of cellular responses to bacterial, mitochondrial, annexinA1 peptide (Ac2-26), W-peptide, and FPRA14 ligands.
• Assessment of agonist potency, efficacy, and pathway bias.

Main Results:

• Bacterial agonists exhibited significantly higher potency and efficacy compared to endogenous agonists.
• No selective pathway activation was observed; both bacterial and mitochondrial agonists showed similar bias towards cAMP formation inhibition.
• FPR1 signaling demonstrated a general agonist bias, not specific to the source of the threat.

Conclusions:

• Biased agonism in FPR1 does not appear to discriminate between bacterial and mitochondrial threat sources.
• The observed bias is consistently towards inhibiting cAMP formation, irrespective of agonist origin.
• FPR1 signaling exhibits source-independent pathway selectivity for transmitting pro-inflammatory danger signals.